The post was specific to siRNA but im not convinced the cardio protect function falls into this category. It was confirmed not to be FTO related.
That said, still think that something is in the pipeline with Novartis up there on the list, cardiovascular and RNA programs being their current focus.
Remember the COH deal requires that Rac proceed with COH development, otherwise breach of contract.
We just don’t have funding so would be a dumb idea for such a commitment without a funding plan. My thoughts, a deal conditional with COH forcing their hand, or, bargaining chip. Either way something is cooking @Kron00
General Comments / Chat, page-8464
-
- There are more pages in this discussion • 3,017 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
0.050(3.08%) |
Mkt cap ! $285.4M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.75 | $1.64 | $210.4K | 125.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 595 | 1 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |